Synergistic Integration of Engineered CMV Glycoprotein B with Emerging Technologies

This inventive concept integrates the engineered mutant of human cytomegalovirus glycoprotein B (CMV gB) with emerging technologies such as artificial intelligence, Internet of Things (IoT), blockchain, and CRISPR-Cas9 gene editing to create a new, more powerful system for detecting, monitoring, and treating human cytomegalovirus infection.

The original patent disclosed engineered mutants of human cytomegalovirus glycoprotein B (CMV gB) with improved stability and efficacy. However, the patent's limitations included the lack of integration with other technologies to enhance its diagnostic and therapeutic capabilities. The new inventive concept addresses this limitation by combining the engineered CMV gB mutant with emerging technologies to create a more comprehensive and effective system.

The new inventive concept comprises a synergistic combination of the engineered CMV gB mutant with artificial intelligence-powered diagnostic algorithms, IoT devices, blockchain-based tracking systems, and CRISPR-Cas9 gene editing systems. The AI-powered diagnostic algorithm is trained on a dataset of patient samples to improve the accuracy of diagnosis. The IoT device tracks and transmits patient data to healthcare providers, enabling real-time monitoring of the infection. The blockchain-based system ensures the authenticity and traceability of the engineered CMV gB mutant. The CRISPR-Cas9 gene editing system targets and edits viral genes to enhance the treatment of human cytomegalovirus infection. The composite material comprising the engineered CMV gB mutant and a nanoparticle enhances the stability and efficacy of the protein.

The new claims introduce a novel and non-obvious integration of the engineered CMV gB mutant with emerging technologies, which provides a synergistic effect and enhances the diagnostic and therapeutic capabilities of the system. The inventive step lies in the unexpected combination of these technologies to create a more powerful system.

Alternative embodiments of the inventive concept could include integrating the engineered CMV gB mutant with other emerging technologies such as machine learning, 5G networks, or biodegradable materials. Variations of the system could include using different types of nanoparticles or gene editing systems to enhance the stability and efficacy of the protein.

The inventive concept has significant commercial potential in the diagnostics and therapeutics markets, particularly in the areas of infectious disease management and personalized medicine. The system could be marketed to healthcare providers, pharmaceutical companies, and biotechnology firms, with potential applications in hospitals, clinics, and research institutions.